Literature DB >> 10790126

Development and evaluation of a molecular viability assay for Pneumocystis carinii.

N Maher1, S Vermund, M Lasbury, C Lee, M Bartlett, T R Unnasch.   

Abstract

Despite recent declines in incidence, Pneumocystis carinii pneumonia (PCP) remains the most commonly occurring opportunistic illness among persons with AIDS in the United States. While P. carinii DNA has been detected in patient respiratory specimens and in air samples collected from various indoor environments housing PCP patients, the viability of these organisms is unknown. For this reason, we have developed and evaluated a molecular viability assay for P. carinii. This method is based upon the detection of P. carinii mRNA by a reverse transcription-PCR that employs specific primers from a member of the heat shock protein 70 family. Under optimal assay conditions, these primers were capable of detecting as few as 100 viable trophozoites as determined by ethidium bromide staining, while no signal was obtained from 10(6) trophozoites killed by heat, desiccation, or UV radiation. This assay was also capable of distinguishing P. carinii from other common fungi present in the air. Therefore, this molecular viability assay may be useful in conjunction with standard bioaerosol collection devices and procedures for the detection of viable P. carinii collected from various indoor environments. It may also be useful in confirming the presence of viable trophozoites in respiratory specimens collected by noninvasive techniques from putatively infected individuals.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10790126      PMCID: PMC86630     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  35 in total

1.  Detection of Pneumocystis carinii DNA in air samples: likely environmental risk to susceptible persons.

Authors:  M S Bartlett; S H Vermund; R Jacobs; P J Durant; M M Shaw; J W Smith; X Tang; J J Lu; B Li; S Jin; C H Lee
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

2.  The HSP70 gene family in Pneumocystis carinii: molecular and phylogenetic characterization of cytoplasmic members.

Authors:  T T Stedman; D R Butler; G A Buck
Journal:  J Eukaryot Microbiol       Date:  1998 Nov-Dec       Impact factor: 3.346

3.  Failure of co-trimoxazole in Pneumocystis carinii infection and mutations in dihydropteroate synthase gene.

Authors:  Q Mei; S Gurunathan; H Masur; J A Kovacs
Journal:  Lancet       Date:  1998-05-30       Impact factor: 79.321

4.  Sensitive and rapid detection of viable Giardia cysts and Cryptosporidium parvum oocysts in large-volume water samples with wound fiberglass cartridge filters and reverse transcription-PCR.

Authors:  C Kaucner; T Stinear
Journal:  Appl Environ Microbiol       Date:  1998-05       Impact factor: 4.792

Review 5.  Pneumocystis carinii pneumonia: a clinical review.

Authors:  A Wilkin; J Feinberg
Journal:  Am Fam Physician       Date:  1999-10-15       Impact factor: 3.292

6.  Continuous axenic cultivation of Pneumocystis carinii.

Authors:  S Merali; U Frevert; J H Williams; K Chin; R Bryan; A B Clarkson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

7.  Oropharyngeal samples for genotyping and monitoring response to treatment in AIDS patients with Pneumocystis carinii pneumonia.

Authors:  Anthony G Tsolaki; Robert F Miller; Ann E Wakefield
Journal:  J Med Microbiol       Date:  1999-10       Impact factor: 2.472

8.  Identification of Pneumocystis carinii f. sp. hominis gene sequences in filtered air in hospital environments.

Authors:  M Olsson; C Lidman; S Latouche; A Björkman; P Roux; E Linder; M Wahlgren
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

Review 9.  Sulfa hypersensitivity in patients with HIV infection: onset, treatment, critical review of the literature.

Authors:  C Ryan; M Madalon; D W Wortham; F M Graziano
Journal:  WMJ       Date:  1998-05

10.  Diagnostic use of PCR for detection of Pneumocystis carinii in oral wash samples.

Authors:  J Helweg-Larsen; J S Jensen; T Benfield; U G Svendsen; J D Lundgren; B Lundgren
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

View more
  7 in total

1.  Pneumocystis melanins confer enhanced organism viability.

Authors:  Crystal R Icenhour; Theodore J Kottom; Andrew H Limper
Journal:  Eukaryot Cell       Date:  2006-06

Review 2.  Molecular and nonmolecular diagnostic methods for invasive fungal infections.

Authors:  Marios Arvanitis; Theodora Anagnostou; Beth Burgwyn Fuchs; Angela M Caliendo; Eleftherios Mylonakis
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

3.  Quantification of Candida albicans actin mRNA by the LightCycler system as a means of assessing viability in a model of cutaneous candidiasis.

Authors:  C N Okeke; R Tsuboi; H Ogawa
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

4.  Development of a rapid real-time PCR assay for quantitation of Pneumocystis carinii f. sp. carinii.

Authors:  Hans Henrik Larsen; Joseph A Kovacs; Frida Stock; Vibeke H Vestereng; Bettina Lundgren; Steven H Fischer; Vee J Gill
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

5.  Immunocompetent hosts as a reservoir of pneumocystis organisms: histological and rt-PCR data demonstrate active replication.

Authors:  M Chabé; E Dei-Cas; C Creusy; L Fleurisse; N Respaldiza; D Camus; I Durand-Joly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-08       Impact factor: 3.267

6.  Pneumocystis infection enhances antibody-mediated resistance to a subsequent influenza infection.

Authors:  James A Wiley; Allen G Harmsen
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

7.  SYTO-13, a Viability Marker as a New Tool to Monitor In Vitro Pharmacodynamic Parameters of Anti-Pneumocystis Drugs.

Authors:  Annie Standaert-Vitse; Cécile-Marie Aliouat-Denis; Anna Martinez; Sara Khalife; Muriel Pottier; Nausicaa Gantois; Eduardo Dei-Cas; El Moukhtar Aliouat
Journal:  PLoS One       Date:  2015-06-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.